No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TXG240621P40000
- 13.88
- 0.000.00%
15min DelayTrading May 15 13:49 ET
0.00High0.00Low
0.00Open13.88Pre Close0 Volume2 Open Interest40.00Strike Price0.00Turnover136.93%IV-0.05%PremiumJun 21, 2024Expiry Date17.94Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9699Delta0.0144Gamma1.23Leverage Ratio-0.0094Theta-0.0075Rho-1.19Eff Leverage0.0033Vega
Intraday
- 5D
- 1D
News
Express News | 10X Genomics Inc : Jefferies Initiates Coverage With Hold Rating; Price Target $24
We're Not Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr
10x Genomics Launches 5,000-Plex Gene Panel for Xenium
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., May 29, 2024 /PRNewswire/ -- 10x Genom
Form 144 | 10x Genomics(TXG.US) Officer Proposes to Sell 100.24K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $10x Genomics(TXG.US)$ Officer Hindson Benjamin J. intends to sell 4,037 shares of its common stock on May 22, with a total market value of approximately $100.24K. Hi
Form 144 | 10x Genomics(TXG.US) Officer Proposes to Sell 125.22K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $10x Genomics(TXG.US)$ Officer Saxonov Serge intends to sell 5,043 shares of its common stock on May 22, with a total market value of approximately $125.22K. Saxonov
10x Genomics Stock Slides Amid German Patent Court Ruling
Comments
$10x Genomics(TXG.US$ no idea what is this even but the chart is so ugly & i love buying ugly charts
2
Analysts predict 10x Genomics will reach cashflow breakeven before depleting its cash reserves. The company appears well-positioned to fund its growth, with options to raise more capital through share issuance or debt.
1
James Wilbur's share sale prompts doubts about insiders’ view of stock's worth. No insider buying in past year may hint at uncertainty in company's future, despite high insider ownership suggesting management's awareness of shareholders' interests.
$10x Genomics(TXG.US$ why the jump up today in price action?
Read more